Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective

Treatment of Complex Regional Pain Syndrome (CRPS): New Perspectives in the use of Sulfonamides as Modulators of P2X Receptors

Author(s): Giulia Culletta, Anna Maria Almerico and Marco Tutone*

Volume 17, Issue 2, 2023

Published on: 17 April, 2023

Page: [88 - 95] Pages: 8

DOI: 10.2174/2772270817666230320124000

Price: $65

« Previous
[1]
Bruehl S. Complex regional pain syndrome. BMJ 2015; 351: h2730.
[http://dx.doi.org/10.1136/bmj.h2730] [PMID: 26224572]
[2]
Harden NR, Bruehl S, Perez RSGM, et al. Validation of proposed diagnostic criteria (the “Budapest Criteria”) for complex regional pain syndrome. Pain 2010; 150(2): 268-74.
[http://dx.doi.org/10.1016/j.pain.2010.04.030] [PMID: 20493633]
[3]
Rondinelli RD, Genovese E, Katz RT, et al. AMA guides to the evaluation of permanent impairment. (6th ed.), Chicago, USA: AMA 2008.
[http://dx.doi.org/10.1001/978-1-57947-888-9]
[4]
Harden RN, Oaklander AL, Burton AW. Complex Regional Pain Syndrome: Practical diagnostic and treatment guidelines, 4th edition. Pain Medicine 2013; 14: 180-229.
[5]
Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 1998; 78(3): 157-69.
[http://dx.doi.org/10.1016/S0304-3959(98)00135-3] [PMID: 9870569]
[6]
Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997; 73(2): 123-39.
[http://dx.doi.org/10.1016/S0304-3959(97)00049-3] [PMID: 9415498]
[7]
Harden RN, Bruehl S, Backonja MM. The use of opioids in treatment of chronic pain: an examination of the ongoing controversy. J Back Musculoskeletal Rehabil 1997; 9(2): 155-80.
[http://dx.doi.org/10.3233/BMR-1997-9207] [PMID: 24573007]
[8]
Harden RN, Bruehl S, Siegler J, Cole PA. Pain, psychological status, and functional recovery in chronic pain patients on daily opioids: a case comparison. J Back Musculoskeletal Rehabil 1997; 9(2): 101-8.
[http://dx.doi.org/10.3233/BMR-1997-9203] [PMID: 24573003]
[9]
Chen L, Malarick C, Seefeld L, Wang S, Houghton M, Mao J. Altered quantitative sensory testing outcome in subjects with opioid therapy. Pain 2009; 143(1): 65-70.
[http://dx.doi.org/10.1016/j.pain.2009.01.022] [PMID: 19237249]
[10]
Angst MS, Clark JD. Opioid-induced Hyperalgesia. Anesthesiology 2006; 104(3): 570-87.
[http://dx.doi.org/10.1097/00000542-200603000-00025] [PMID: 16508405]
[11]
FDA. Drug Safety Communication. Available from: http://www.fda.gov/media/133681/download
[12]
Mackey S, Feinberg S. Pharmacologic therapies for complex regional pain syndrome. Curr Pain Headache Rep 2007; 11(1): 38-43.
[http://dx.doi.org/10.1007/s11916-007-0020-z] [PMID: 17214920]
[13]
European Medicines Agency. Public summary of opinion on orphan designation: zoledronic acid for the treatment of complex regional pain syndrome. Available from: www.ema.europa.eu
[14]
US Food and Drug Administration. Orphan drug designations and approvals 2013. Available from: www.accessdata.fda.gov
[15]
Ackerman WE III, Ahmad M. Recurrent postoperative CRPS I in patients with abnormal preoperative sympathetic function. J Hand Surg Am 2008; 33(2): 217-22.
[http://dx.doi.org/10.1016/j.jhsa.2007.10.017] [PMID: 18294544]
[16]
Molnár K, Nógrádi B, Kristóf R, et al. Motoneuronal inflammasome activation triggers excessive neuroinflammation and impedes regeneration after sciatic nerve injury. J Neuroinflammation 2022; 19(1): 68.
[http://dx.doi.org/10.1186/s12974-022-02427-9] [PMID: 35305649]
[17]
Rodrigues RJ, Tomé AR, Cunha RA. ATP as a multi-target danger signal in the brain. Front Neurosci 2015; 9: 148.
[http://dx.doi.org/10.3389/fnins.2015.00148] [PMID: 25972780]
[18]
Habermacher C, Dunning K, Chataigneau T, Grutter T. Molecular structure and function of P2X receptors. Neuropharmacology 2016; 104: 18-30.
[http://dx.doi.org/10.1016/j.neuropharm.2015.07.032] [PMID: 26231831]
[19]
Robinson LE, Murrell-Lagnado RD. The trafficking and targeting of P2X receptors. Front Cell Neurosci 2013; 7: 233.
[http://dx.doi.org/10.3389/fncel.2013.00233] [PMID: 24319412]
[20]
Kawate T, Michel JC, Birdsong WT, Gouaux E. Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 2009; 460(7255): 592-8.
[http://dx.doi.org/10.1038/nature08198] [PMID: 19641588]
[21]
Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 2012; 485(7397): 207-12.
[http://dx.doi.org/10.1038/nature11010] [PMID: 22535247]
[22]
Zhang W, Luo H, Zhu Z. The role of P2X4 receptors in chronic pain: A potential pharmacological target. Biomed Pharmacother 2020; 129: 110447.
[http://dx.doi.org/10.1016/j.biopha.2020.110447] [PMID: 32887026]
[23]
Antonio LS, Stewart AP, Xu XJ, Varanda WA, Murrell-Lagnado RD, Edwardson JM. P2X4 receptors interact with both P2X2 and P2X7 receptors in the form of homotrimers. Br J Pharmacol 2011; 163(5): 1069-77.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01303.x] [PMID: 21385174]
[24]
Wareham K, Vial C, Wykes RCE, Bradding P, Seward EP. Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells. Br J Pharmacol 2009; 157(7): 1215-24.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00287.x] [PMID: 19552691]
[25]
Boumechache M, Masin M, Edwardson JM, Górecki DC, Murrell-Lagnado R. Analysis of assembly and trafficking of native P2X4 and P2X7 receptor complexes in rodent immune cells. J Biol Chem 2009; 284(20): 13446-54.
[http://dx.doi.org/10.1074/jbc.M901255200] [PMID: 19304656]
[26]
Tsuda M, Shigemoto-Mogami Y, Koizumi S, et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003; 424(6950): 778-83.
[http://dx.doi.org/10.1038/nature01786] [PMID: 12917686]
[27]
Tsuda M, Kuboyama K, Inoue T, Nagata K, Tozaki-Saitoh H, Inoue K. Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays Mol Pain 2009; 5: 1744-8069-5-28.
[http://dx.doi.org/10.1186/1744-8069-5-28] [PMID: 19515262]
[28]
Coull JAM, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005; 438(7070): 1017-21.
[http://dx.doi.org/10.1038/nature04223] [PMID: 16355225]
[29]
Ulmann L, Hatcher JP, Hughes JP, et al. Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci 2008; 28(44): 11263-8.
[http://dx.doi.org/10.1523/JNEUROSCI.2308-08.2008] [PMID: 18971468]
[30]
Ulmann L, Hirbec H, Rassendren F. P2X4 receptors mediate PGE2 release by tissue-resident macrophages and initiate inflammatory pain. EMBO J 2010; 29(14): 2290-300.
[http://dx.doi.org/10.1038/emboj.2010.126] [PMID: 20562826]
[31]
Stokes L, Layhadi JA, Bibic L, Dhuna K, Fountain SJ. P2X4 receptor function in the nervous system and current breakthroughs in pharmacology. Front Pharmacol 2017; 8: 291.
[http://dx.doi.org/10.3389/fphar.2017.00291] [PMID: 28588493]
[32]
Tian M, Abdelrahman A, Weinhausen S, et al. Carbamazepine derivatives with P2X4 receptor-blocking activity. Bioorg Med Chem 2014; 22(3): 1077-88.
[http://dx.doi.org/10.1016/j.bmc.2013.12.035] [PMID: 24411477]
[33]
Wang M, Gao M, Meyer JA, et al. Synthesis and preliminary biological evaluation of radiolabeled 5-BDBD analogs as new candidate PET radioligands for P2X4 receptor. Bioorg Med Chem 2017; 25(14): 3835-44.
[http://dx.doi.org/10.1016/j.bmc.2017.05.031] [PMID: 28554730]
[34]
Zech A, Wiesler B, Ayata CK, et al. P2rx4 deficiency in mice alleviates allergen-induced airway inflammation. Oncotarget 2016; 7(49): 80288-97.
[http://dx.doi.org/10.18632/oncotarget.13375] [PMID: 27863396]
[35]
Ase AR, Honson NS, Zaghdane H, Pfeifer TA, Séguéla P. Identification and characterization of a selective allosteric antagonist of human P2X4 receptor channels. Mol Pharmacol 2015; 87(4): 606-16.
[http://dx.doi.org/10.1124/mol.114.096222] [PMID: 25597706]
[36]
Hernandez-Olmos V, Abdelrahman A, El-Tayeb A, Freudendahl D, Weinhausen S, Müller CE. N-substituted phenoxazine and acridone derivatives: Structure-activity relationships of potent P2X4 receptor antagonists. J Med Chem 2012; 55(22): 9576-88.
[http://dx.doi.org/10.1021/jm300845v] [PMID: 23075067]
[37]
Werner S, Mesch S, Hillig RC, et al. Discovery and characterization of the potent and selective P2X4 inhibitor N -[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile. J Med Chem 2019; 62(24): 11194-217.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01304] [PMID: 31746599]
[38]
Acuña-Castillo C, Morales B, Huidobro-Toro JP. Zinc and copper modulate differentially the P2X4 receptor. J Neurochem 2000; 74(4): 1529-37.
[http://dx.doi.org/10.1046/j.1471-4159.2000.0741529.x] [PMID: 10737610]
[39]
Wildman SS, King BF, Burnstock G. Modulation of ATP-responses at recombinant rP2X4 receptors by extracellular pH and zinc. Br J Pharmacol 1999; 126(3): 762-8.
[http://dx.doi.org/10.1038/sj.bjp.0702325] [PMID: 10188989]
[40]
Asatryan L, Ostrovskaya O, Lieu D, Davies DL. Ethanol differentially modulates P2X4 and P2X7 receptor activity and function in BV2 microglial cells. Neuropharmacology 2018; 128: 11-21.
[http://dx.doi.org/10.1016/j.neuropharm.2017.09.030] [PMID: 28943285]
[41]
Tutone M, Virzì A, Almerico AM. Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent. J Theor Biol 2018; 455: 147-60.
[http://dx.doi.org/10.1016/j.jtbi.2018.07.017] [PMID: 30030079]
[42]
Pibiri I, Lentini L, Melfi R, et al. Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs. Eur J Med Chem 2018; 159: 126-42.
[http://dx.doi.org/10.1016/j.ejmech.2018.09.057] [PMID: 30278331]
[43]
Tutone M, Pibiri I, Perriera R, et al. Pharmacophore-based design of new chemical scaffolds as translational readthrough-inducing drugs (TRIDs). ACS Med Chem Lett 2020; 11(5): 747-53.
[http://dx.doi.org/10.1021/acsmedchemlett.9b00609] [PMID: 32435380]
[44]
Kasuya G, Fujiwara Y, Tsukamoto H, et al. Structural insights into the nucleotide base specificity of P2X receptors. Sci Rep 2017; 7(1): 45208.
[http://dx.doi.org/10.1038/srep45208] [PMID: 28332633]
[45]
Ase AR, Therrien É, Séguéla P. An Allosteric Inhibitory Site Conserved in the Ectodomain of P2X Receptor Channels. Front Cell Neurosci 2019; 13: 121.
[http://dx.doi.org/10.3389/fncel.2019.00121] [PMID: 31024257]
[46]
Culletta G, Tutone M, Zappalà M, Almerico AM. Sulfonamide moiety as “molecular chimera” in the design of new drugs. Curr Med Chem 2022; 30: 128-63.
[PMID: 35909290]
[47]
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386(4): 316-26.
[http://dx.doi.org/10.1056/NEJMoa2109927] [PMID: 35081280]
[48]
ten Hove MW, Friedman DI, Patel AD, Irrcher I, Wall M, McDermott MP. Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol 2016; 36(1): 13-9.
[http://dx.doi.org/10.1097/WNO.0000000000000322] [PMID: 26587993]
[49]
Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001; 45(1): 30-7.
[http://dx.doi.org/10.1128/AAC.45.1.30-37.2001] [PMID: 11120940]
[50]
Desantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000; 44 (Suppl. 2): S119-29.
[http://dx.doi.org/10.1016/S0039-6257(99)00108-3] [PMID: 10665514]
[51]
Pergakis M, Badjatia N, Chaturvedi S, et al. BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema. Expert Opin Investig Drugs 2019; 28(12): 1031-40.
[http://dx.doi.org/10.1080/13543784.2019.1681967] [PMID: 31623469]
[52]
Supuran CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 2003; 12(2): 283-7.
[http://dx.doi.org/10.1517/13543784.12.2.283] [PMID: 12556221]
[53]
Sonpavde G, Hutson TE. Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007; 9(2): 115-9.
[http://dx.doi.org/10.1007/s11912-007-0007-2] [PMID: 17288876]
[54]
Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; 1998(2): CD000958.
[PMID: 10796400]
[55]
Lepola U, Koskinen T, Rimón R, Salo H, Gordin A. Sulpiride and perphenazine in schizophrenia. Acta Psychiatr Scand 1989; 80(1): 92-6.
[http://dx.doi.org/10.1111/j.1600-0447.1989.tb01305.x] [PMID: 2669445]
[56]
Culletta G, Allegra M, Almerico AM, Restivo I, Tutone M. In silico design, synthesis, and biological evaluation of anticancer arylsulfonamide endowed with anti-telomerase activity. Pharmaceuticals (Basel) 2022; 15(1): 82.
[http://dx.doi.org/10.3390/ph15010082] [PMID: 35056139]
[57]
Müller CE, Namasivayam V. Recommended tool compounds and drugs for blocking P2X and P2Y receptors. Purinergic Signal 2021; 17(4): 633-48.
[http://dx.doi.org/10.1007/s11302-021-09813-7] [PMID: 34476721]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy